Selenia
February 2, 2010 - Hologic reported its first quarter 2010 net income was $26.1 million, or 10 cents per diluted share, calculated in accordance with U.S. generally accepted accounting principles (GAAP).
A manufacturer of women's diagnostic medical devices, currently Hologic holds a leading position in nine technology areas serving women's health, including breast cancer diagnosis and treatment, cervical cancer screening, prenatal testing, and osteoporosis detection.
First quarter 2010 non-GAAP adjusted net income reached $74.6 million, or 29 cents per diluted share, and adjusted EBITDA (non-GAAP adjusted earnings before interest, taxes, depreciation and amortization) was $147.2 million.
The company reduced its term loan to fund on the Third Wave Technologies acquisition from an initial balance of $540 million at July 24, 2008 to $119.5 million as Dec. 26, 2009, and further reduced to $97 million as of today.
In January 2010, Hologic received $70 million from KV Pharmaceutical Company in connection with an amendment of the original asset purchase agreement relating to the sale of our Gestiva assets.
For more information: www.hologic.com
July 29, 2024 
